← All drugs Report issue

gi-6301

Vaccineexperimental

Clinical trial activity

13 trials · 2 clinical orgs · 0 marketing orgs

Phase 1

9

Phase 2

12

Phase 3

0

Phase 4

0

Earliest trial started Jan 1, 2012 (NCT01519817)

Timeline

2010s

Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Jan 1, 2015
Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

T-box transcription factor TBX5Immunity, active
TBX5 immunity, active
- T-box transcription factor TBX5 (TBX5) ↗

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

gi-6301

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT03554109	Phase 2	Sep 30, 2018	NantWorks
NCT03574649	Phase 2	Sep 30, 2018	NantWorks
NCT03647423	Phase 1/Phase 2 (Phase 2)	Aug 31, 2018	NantWorks
NCT03563144	Phase 2	Aug 31, 2018	NantWorks
NCT03586869	Phase 1/Phase 2 (Phase 2)	Jul 28, 2018	NantWorks
NCT03563157	Phase 1/Phase 2 (Phase 2)	May 25, 2018	NantWorks
NCT03563170	Phase 1/Phase 2 (Phase 2)	May 25, 2018	NantWorks
NCT03387085	Phase 1/Phase 2 (Phase 2)	Mar 16, 2018	NantWorks
NCT03387111	Phase 1/Phase 2 (Phase 2)	Jan 13, 2018	NantWorks
NCT03197571	Phase 1/Phase 2 (Phase 2)	Dec 31, 2017	NantWorks
NCT03197584	Phase 1/Phase 2 (Phase 2)	Dec 31, 2017	NantWorks
NCT02383498	Phase 2	Apr 15, 2015	National Cancer Institute (NCI)
NCT01519817	Phase 1	Jan 1, 2012	National Cancer Institute (NCI)

Showing 13 of 13 trials

Page 1 / 1

Organizations

Research & Development (2)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
NantWorks	For profit	11	11	1	2017
National Cancer Institute (NCI)	Government	2	2	2	2012

2 organizations

Page 1 / 1